Aarti Pharma Labs Share News - Latest Updates, Live News & More

Latest news about Aarti Pharma Labs

Aarti Pharma Labs shares worth ₹62.93 crore flag large-trade signal 2 days ago

Approximately 765,697 shares of Aarti Pharma Labs flagged in a large-trade signal on NSE. Shares changed hands at ₹821.9 per share, for a combined value of ₹62.93 crore. This is a real-time signal generated by a trade-scanning system, not a confirmed exchange-reported event. Buyer, seller, and broker identity are not available until the exchange discloses post-market data.

Aarti Pharmalabs faces ₹59.5 crore stamp duty penalty over demerger Sep 02, 2026

Aarti Pharmalabs schedules 7th AGM for September 22, 2026 Aug 30, 2026

Aarti Pharmalabs files FY26 sustainability report with stock exchanges Aug 29, 2026

Aarti Pharmalabs schedules 7th AGM for September 22 via video conference Aug 29, 2026

More news about Aarti Pharma Labs

18Aug 26

Aarti Pharmalabs sets Sept 15 record date for ₹2 final dividend

Aarti Pharmalabs Limited has announced the record date for its final dividend payout for FY26. Shareholders on record as of September 15, 2026, will be eligible for the recommended ₹2.00 per share dividend, pending approval at the 7th AGM scheduled for September 22, 2026.

17Aug 26

Aarti Pharmalabs Q1 Results: Net profit up 49% YoY to ₹71 crore

Aarti Pharmalabs posted a 49% YoY rise in Q1FY27 net profit to ₹71 crore, driven by a 42% revenue jump to ₹535 crore. Xanthine derivatives led growth with record sales, contributing 57% of turnover. The company completed key capacity expansions in steroids and xanthine, with new CDMO facilities coming online. Full-year EBITDA margin guidance stands at 22-25%.

10Aug 26

Aarti Pharmalabs Q1 Results: Consolidated Net Profit Rises 65% YoY

Aarti Pharmalabs reported a 65.4% YoY rise in consolidated net profit to ₹761 crore in Q1FY27, driven by margin expansion and CDMO growth. Revenue surged 38.7% to ₹5,358 crore, with EBITDA margins at 24.75%. The company also announced a ₹149 crore capex for Atali Block 2.

09Aug 26

Aarti Pharmalabs Q1 Results: Consolidated revenue surges 118% YoY

Aarti Pharmalabs reported a consolidated net loss of ₹27.87 lakh for Q1FY26, a marked improvement from ₹1,156.89 lakh in Q1FY25. Consolidated revenue surged 117.5% YoY to ₹2,441.41 lakh. Standalone operations recorded a net loss of ₹33.56 lakh on income of ₹115.34 lakh.

08Aug 26

Aarti Pharma Labs Q1 Results: Net Profit Jumps to ₹761M YoY

Aarti Pharma Labs reported Q1 consolidated net profit of ₹761M, up from ₹460M year-on-year. Revenue grew to ₹5.36B from ₹3.86B over the same period. EBITDA rose to ₹1.36B from ₹952M, with EBITDA margin improving to 25.40% from 24.66% year-on-year, reflecting strong operational performance across the board.

08Aug 26

Aarti Pharmalabs director Rajendra Gogri steps down

Rajendra Vallabhaji Gogri, Non-Executive Director of Aarti Pharmalabs Limited, will not offer himself for re-appointment due to personal commitments. His tenure ends at the close of business on the date of the ensuing AGM, where he is liable to retire by rotation.

03Aug 26

Aarti Pharmalabs Q1 Results: Earnings call scheduled for Aug 10

Aarti Pharmalabs Limited has scheduled an earnings conference call for August 10, 2026, at 4:00 PM IST to discuss Q1FY27 results. Chairman Rashesh Gogri, Vice Chairperson Hetal Gogri Gala, and CFO Piyush Lakhani will lead the discussion. The filing complies with SEBI LODR Regulation 30 and was submitted to BSE and NSE.

01Jul 26

Aarti Pharmalabs expands Xanthine derivatives capacity to 9600 TPA

Aarti Pharmalabs Limited inaugurated a new manufacturing block at Tarapur Unit 5 on June 30, 2026, adding 3600 TPA capacity for Xanthine derivatives. With total capacity reaching 9600 TPA, the company positions itself among the top three global manufacturers. Trial production has begun, with plans to ramp up for optimum utilization in the coming quarters.

02Jun 26

Aarti Pharmalabs targets 15-18% revenue and EBITDA growth over 3-4 years

Aarti Pharmalabs Limited reported a 35.9% decline in consolidated net profit for FY26 to ₹1,747 million, impacted by fair value losses and new labour codes, while revenue decreased 14% to ₹18,194 million. Despite this, management targets 15-18% revenue and EBITDA growth over the next 3-4 years, driven by a 40-50% projected sales increase in the CDMO/CMO business. The Board recommended a final dividend of ₹2 per share and approved the FY26 capital expenditure of approximately ₹400 crore.

27May 26

Aarti Pharmalabs uploads Q4FY26 earnings call recording

Aarti Pharmalabs Limited has uploaded the audio recording of its earnings conference call for the fourth quarter and financial year ended March 31, 2026. The disclosure, compliant with Regulation 30 of the SEBI (LODR) Regulations, 2015, allows stakeholders to access management commentary on the company's performance via a link on its official website.

21May 26

AARTI PHARMALABS meets investors on May 28

AARTI PHARMALABS LIMITED is scheduled to meet investors and analysts on May 28, 2026, during the 360 ONE Capital Conference - Trinity 2026. The meeting will be conducted in physical mode to discuss the ordinary course of business. The company confirmed that no unpublished price sensitive information will be shared.

14May 26

Aarti Pharmalabs Postpones Board Meeting to May 25, 2026 for FY26 Results and Dividend

Aarti Pharmalabs Limited has rescheduled its Board of Directors meeting from May 18 to May 25, 2026, to consider audited financial results for Q4 and the full financial year ended March 31, 2026, and to deliberate on a final dividend recommendation. The Trading Window for securities transactions has been extended and will remain closed until May 27, 2026, i.e., 48 hours after the declaration of financial results.

07Apr 26

Aarti Pharmalabs Limited Submits SEBI Compliance Certificate for Q4 FY26

Aarti Pharmalabs Limited filed its mandatory SEBI compliance certificate for Q4 FY26 on April 07, 2026, covering the quarter ended March 31, 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirmed no dematerialisation requests were received during the quarter. Company Secretary Jeevan Mondkar submitted the filing to both BSE and NSE, maintaining the company's regulatory compliance under SEBI (Depositories and Participants) Regulations, 2018.

07Apr 26

Aarti PharmaLabs Publishes Saksham Niveshak Campaign Advertisements Under Regulation 30

Aarti PharmaLabs Limited informed stock exchanges about publishing newspaper advertisements for its Second 100-Day Campaign 'Saksham Niveshak' under Regulation 30 compliance. The campaign runs from April 01 to July 09, 2026, targeting shareholders with unclaimed dividends from 2022-23 to 2025-26, requiring KYC updates to prevent transfer to IEPF.

04Apr 26

Aarti Pharmalabs Promoter Pledges 27.84 Lakh Shares Worth ₹177.90 Crore

Aarti Pharmalabs promoter Mr. Mirik Rajendra Gogri has pledged 27,84,094 shares representing 3.08% of the company's share capital to two financial institutions - Bajaj Financial Securities Limited and 360 One Distribution Services Limited. The pledge, created on March 25, 2026, secures a borrowing of ₹75 crore against shares valued at ₹177.90 crore, providing a security cover ratio of 2.37. The encumbered shares represent only 7% of his total promoter holding of 43.10%.

04Apr 26

Aarti Pharmalabs Promoter Pledges 15.20 Lakh Shares Under Regulation 31

Aarti Pharmalabs Limited disclosed that promoter Mr. Renil Rajendra Gogri created a pledge of 15,19,919 shares representing 1.68% of the company's share capital in favor of three financial institutions - Aditya Birla Capital Limited, Bajaj Financial Securities Limited, and 360 One Distribution Services Limited. The pledge, valued at INR 97,12,28,241, was created on March 25, 2026, for personal use and represents 3.89% of the promoter's total shareholding of 43.10% in the company.

28Mar 26

Aarti Pharmalabs Receives Single FDA Form 483 Observation for Tarapur Unit-IV Following Inspection

Aarti Pharmalabs Limited has received a single procedural Form 483 observation from the US FDA following inspection of its Tarapur Unit-IV manufacturing facility. The inspection concluded on March 27, 2026, and the company has formally notified BSE and NSE under SEBI Regulation 30, committing to submit corrective and preventive actions within the stipulated timeframe.

24Mar 26

Aarti Pharmalabs Reports Chemical Leak at Tarapur Unit Under SEBI Regulation 30

Aarti Pharmalabs Limited reported a minor chemical leak incident at its Tarapur facility under SEBI Regulation 30 compliance. The incident involved dimethyl sulphate during tanker loading operations, resulting in 22 workers being hospitalized for precautionary observation. With no casualties or property damage, normal operations resumed within 24 hours while investigation proceedings continue.

13Feb 26

Aarti Pharmalabs Limited Clarifies Delay in Regulatory Disclosure to BSE

Aarti Pharmalabs Limited has clarified to BSE the reason behind a delayed regulatory disclosure under SEBI Regulation 30. The company explained that the required 24-hour disclosure timeline was missed because the concerned official was on leave from February 3-5, 2026, and the matter came to attention only upon their return. The clarification was submitted on February 13, 2026, with the company requesting BSE to take the explanation on record and emphasizing that the delay was inadvertent.

11Feb 26

Aarti Pharmalabs Q3FY26 Results and Earnings Call Recording Now Available

Aarti Pharmalabs delivered mixed Q3FY26 results with operational revenue of INR 4,253 million, showing sequential growth but year-on-year decline. The company demonstrated strong EBITDA margin recovery to 24.22% and continues expanding its Xanthine capacity while managing operational challenges at Atali facility.

11Feb 26

Aarti Pharmalabs Issues Corrigendum to Dividend Record Date Intimation for FY26

Aarti Pharmalabs Limited filed a corrigendum on February 10, 2026, to correct a typographical error in its dividend record date intimation from the previous day. The company clarified that the dividend was declared for Financial Year 2025-26, not 2024-25 as incorrectly mentioned earlier. Company Secretary Jeevan Mondkar confirmed no other changes were made to the original filing, ensuring accurate regulatory compliance with both BSE and NSE.

09Feb 26

Aarti Pharmalabs Allots 10,457 Equity Shares Under Performance Stock Option Plan 2023

Aarti Pharmalabs Limited allotted 10,457 equity shares of Rs. 5 face value each to employees under PSOP 2023 on February 09, 2026. The allotment increased the company's paid-up equity capital to Rs. 45,32,88,755, representing 9,06,57,751 total shares. The newly issued shares rank pari-passu with existing equity shares and comply with SEBI regulations.

06Feb 26

Aarti Pharmalabs Limited Receives Rs 2.60 Lakh Penalty from CGST Authority

Aarti Pharmalabs Limited has received a Rs 2.60 lakh penalty from CGST and Central Excise authority under Section 74 of CGST Act, 2017. The penalty is part of a larger demand of Rs 31,15,608 related to alleged excess Input Tax Credit availment and incorrect tax liability declarations for FY2022-23 and FY2023-24. The company states no material impact on financials or operations is expected.

02Feb 26

Aarti Pharmalabs Limited Schedules Q3FY26 Earnings Conference Call for February 10, 2026

Aarti Pharmalabs Limited has scheduled its Q3FY26 earnings conference call for February 10, 2026 at 4:00 PM IST. The group meeting will feature Chairman Mr. Rashesh Gogri, Vice Chairperson Mrs. Hetal Gogri Gala, and CFO Mr. Piyush Lakhani discussing quarterly financial results. The company has provided domestic and international dial-in access, with toll-free numbers available for Hong Kong, Singapore, USA, and UK participants.

01Jan 26

Aarti Pharmalabs Limited Appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D

Aarti Pharmalabs Limited has appointed Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D effective January 01, 2026, following Board approval based on Nomination and Remuneration Committee recommendation. Dr. Bandichhor brings 25 years of experience in API-R&D and Process Chemistry, with strong academic credentials including M.Sc. degrees and Ph.D. in Chemistry, plus postdoctoral training from universities in Germany and USA. He was previously associated with Dr. Reddy's Laboratories in Hyderabad.

17Nov 25

Aarti Pharmalabs Reports 11% Revenue Growth in Q2FY26, Revises EBITDA Growth Guidance

Aarti Pharma Labs reported a 11% year-on-year revenue growth for Q2FY26, reaching INR 417.00 crores. However, EBITDA declined to INR 75.00 crores from INR 85.00 crores, and PAT decreased to INR 31.00 crores from INR 48.00 crores. The company's Xanthine Derivatives segment contributed 51% to turnover, API and Intermediates 39%, and CDMO-CMO Services 10%. The Atali plant was inaugurated in September, and Xanthine expansion is progressing as planned. Aarti Pharma Labs revised its FY26 EBITDA growth guidance to 8-12% year-on-year, with the CDMO-CMO business expected to exceed earlier projections.

09Nov 25

Aarti Pharmalabs Reports Strong Q2 Performance with 11% Revenue Growth

Aarti Pharma Labs announced unaudited Q2 and H1 FY2026 results. Q2 standalone revenue increased 11.2% to Rs 417.29 crore, with net profit up 45.3% to Rs 30.85 crore. H1 FY2026 revenue grew 2.8% to Rs 792.60 crore, while net profit rose 8.9% to Rs 52.08 crore year-over-year. The company operates in the pharmaceuticals segment and has global subsidiaries including Aarti USA Inc and Aarti Pharmachem Ltd. A joint venture with Ganesh Polychem Limited became effective from April 1, 2025.

09Nov 25

Aarti Pharma Labs Bolsters Leadership with Two Key Senior Management Appointments

Aarti Pharma Labs Limited has announced two significant appointments to its senior management team, effective November 10, 2025. Mr. Hemant Gundare, with a doctorate in Green Chemistry, joins as Head Corporate - EHS (Environment, Health & Safety). Mr. Shrihari S. Mane, with 32 years of experience in API manufacturing, has been appointed as Chief Technology Officer (API). These appointments, approved by the Board of Directors on November 9, 2025, aim to enhance the company's environmental sustainability, safety practices, and technological capabilities in API manufacturing.

Aarti Pharma Labs

853.50

+33.10

(+4.03%)

1 Year Returns:-5.20%

Industry Peers

Sun Pharmaceutical

1,875.00

(+2.05%)

Divis Laboratories

9,395.50

(+0.22%)

Torrent Pharmaceuticals

4,964.00

(+2.56%)

Zydus Life Science

1,154.60

(-0.47%)

Cipla

1,380.70

(-0.99%)

Laurus Labs

2,015.00

(+3.12%)

Mankind Pharma

2,439.00

(+6.01%)

Dr Reddys Laboratories

1,204.10

(+1.61%)

Aurobindo Pharma

1,715.70

(-1.06%)

Lupin

2,108.10

(+1.20%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104